Lyme borreliosis treatment
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
18394084
DOI
10.1111/j.1529-8019.2008.00177.x
PII: DTH177
Knihovny.cz E-resources
- MeSH
- Acrodermatitis drug therapy microbiology MeSH
- Anti-Bacterial Agents administration & dosage therapeutic use MeSH
- Antibiotic Prophylaxis * MeSH
- Child MeSH
- Adult MeSH
- Erythema Chronicum Migrans drug therapy microbiology MeSH
- Humans MeSH
- Lyme Disease complications diagnosis drug therapy microbiology pathology MeSH
- Adolescent MeSH
- Treatment Failure MeSH
- Pseudolymphoma drug therapy microbiology MeSH
- Drug Administration Schedule MeSH
- Practice Guidelines as Topic MeSH
- Pregnancy MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
Lyme borreliosis is the most common human tick-borne illness in the Northern Hemisphere. The causative agent is the spirochete Borrelia burgdorferi species complex, and the hard-shell ticks of the genus Ixodes is responsible for pathogen transmission from animals to humans. The incidence of the disease is increasing year by year and although lyme disease is not fatal, it can affect the skin, heart, nervous, and musculoskeletal system with an impairment of quality of life. The appropriate diagnosis of lyme disease should be promptly treated by antibiotics to prevent late stage of the disease. The choice of antibiotics depends on many factors such as the stage of the disease, the drug efficacy, adverse effects, type of delivery, duration of treatment, and cost. Treatment failure occurs as a result of many reasons, re-infection is possible. The recommended treatment schedule in the Czech Republic is presented.
References provided by Crossref.org